论文部分内容阅读
目前尚无可确定血小板活性与动脉粥样硬化并发症关系的血小板功能试验。因此,寻找一种与冠心病患者预后相关的血小板功能试验尤为重要。为此,作者测定了新近心肌梗塞(MI)患者的体外血小板自然凝集(SPA),并随访5年,以探讨SPA与MI患者死亡率和复发率的关系。病人和方法作者对<71岁的MI患者149例的SPA进行了测定。由于急性心肌缺血会影响血小板的功能,故于MI后3个月时首次测定SPA。以后每6个月测1次,随访5年。每次测SPA前1周,所有患者均停服抗血小板药物。于上午9～10时采静脉血9ml,置入含3.2%枸橼酸钠的塑料管中。室温下放置15min后离心10min,得出富含血小板的血浆。
There are currently no platelet function tests that determine the relationship between platelet activity and atherosclerotic complications. Therefore, finding a platelet function test related to the prognosis of patients with coronary heart disease is particularly important. To do this, we determined in vitro platelet aggregation (SPA) in patients with recent myocardial infarction (MI) and followed up for 5 years to investigate the association between mortality and relapse rates in patients with SPA and MI. Patients and Methods The authors determined the SPA of 149 patients <71 years old with MI. Since acute myocardial ischemia affects the function of platelets, SPA was first measured at 3 months after MI. After every 6 months to measure 1, followed up for 5 years. One week before each SPA test, all patients stopped taking antiplatelet drugs. At 9 am to 10 am venous blood 9ml, placed in 3.2% sodium citrate plastic tube. After 15 min at room temperature, centrifuge for 10 min to obtain platelet-rich plasma.